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Abstract
Background: A cohort study was conducted to examine the role of genetic polymorphisms in
three estrogen metabolizing enzymes (COMT, CYP1A1, CYP1B1) and the two estrogen receptors
(ESR1, ESR2) in the progression of benign breast disease (BBD) to breast cancer.
Methods: Among participants in an ongoing cohort study, 1438 Caucasian women had a breast
biopsy for BBD and were successfully genotyped for at least one of the polymorphisms examined
in this study. Genotypes were determined using DNA extracted from blood specimens collected
in 1989. Incident cases of breast cancer occurring subsequent to BBD diagnosis up to 2003 were
identified through cancer registries.
Results: Among all participants, the ESR2 *5772G allele was associated with a significant decrease
in the risk of breast cancer among women with BBD (Odds Ratio (OR) 0.38; 95% Confidence
Interval (CI) 0.15, 0.96). Compared to the reference wild-type genotypes, marginally significant
associations with the development of breast cancer were observed between carriers of the variant
ESR1 – 104062T allele (OR 0.70, 95% CI 0.45, 1.09), the variant ESR2 *38A allele (OR 1.40; 95% CI
0.88, 2.25), and the variant CYP1B1 453Ser allele (OR 1.48, 95% CI 0.95, 2.32).
Conclusion: The results indicate that specific polymorphisms in the CYP1B1, ESR1, and ESR2 genes
may play a role in progression of BBD to breast cancer among Caucasian women. Although
additional studies are needed to confirm or refute our findings, these results suggest that genetic
markers may aid in the identification of women who are at risk for progression of BBD to cancer.
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Background
Biopsy-proven benign breast disease (BBD) is a well-
defined risk factor for developing invasive breast cancer
[1,2]. However, little is known about which women with
BBD progress to have a subsequent in situ or invasive can-
cer. A woman's level of endogenous estrogen may be
important in the progression of BBD to invasive breast
cancer. Abundant evidence suggests that estrogen is an
important factor in the development of breast cancer
among average-risk women. This evidence includes find-
ings from recent prospective studies that showed signifi-
cantly increased levels of serum estrogen in women who
developed breast cancer compared to women who did not
develop breast cancer [3-7]. In addition, numerous stud-
ies have reported that risk factors associated with pro-
longed estrogen exposure, such as early age at menarche,
nulliparity, and older age at first birth, increase a woman's
risk of developing breast cancer (reviewed by Mitrunen
and Hirvonen [8]).
Because of the importance of estrogen in the development
of breast cancer among average-risk women, it is plausible
that polymorphisms in estrogen metabolizing genes may
be associated with the risk of developing breast cancer
among women with BBD. Estrogens undergo oxidative
metabolism by several cytochrome P450 (CYPs) enzymes
[9]; the major metabolic pathways are 2-hydroxylation,
which is primarily catalyzed by CYP1A1, and 4-hydroxyla-
tion, which is dominated by CYP1B1 [10]. The hydroxy-
lated estrogens are then either converted to semiquinones
or quinones, which can produce DNA adducts and lead to
oxidative damage to lipids and DNA, or inactivated by cat-
echol O-methyltransferase (COMT) [10-13]. Within the
genes encoding for CYP1A1,  CYP1B1, and COMT, a
number of polymorphisms have been identified, some
which have been shown in laboratory studies to be func-
tional (8). The associations of some of these polymor-
phisms with the risk of developing breast cancer among
average risk women have been studied, and most of the
findings have been inconsistent (reviewed in Mitrunen
and Hirvonen [8]). No study has examined the associa-
tions of polymorphisms in CYP1A1, CYP1B1, and COMT
with breast cancer risk among women with BBD.
While the estrogen metabolizing enzymes may influence
the levels of circulating endogenous estrogens and, there-
fore, contribute to breast cancer risk, the estrogen recep-
tors determine, in part, the action of estrogens on the
mammary gland. Estrogen acts on target tissues by bind-
ing to the estrogen receptors, which exist in two forms, ER-
α or ESR1 and ER-β or ESR2 [14,15]. Like the estrogen
metabolizing enzymes, a number of polymorphisms in
both ER genes have been identified [16], and it has been
hypothesized that these polymorphisms may increase or
decrease a woman's breast cancer risk depending on the
functional consequence of the polymorphism. Several
studies have investigated the associations between poly-
morphisms in the ESR1 and ESR2 genes and the risk of
breast cancer among average-risk women and have
reported mixed results [16-29]. To our knowledge, how-
ever, no study has examined the associations of polymor-
phisms in ESR1 and ESR2 with breast cancer risk among
women with BBD.
The aim of the present study was to analyze the associa-
tions between genetic polymorphisms in three estrogen
metabolizing enzymes (COMT,  CYP1A1,  CYP1B1) and
the two estrogen receptors (ESR1, ESR2) and the risk of
developing breast cancer among women with BBD. To
address this aim, data from a cohort of women with BBD
from Washington County, Maryland enrolled in the
CLUE-II study were analyzed.
Methods
CLUE II cohort
In 1989, a campaign named CLUE II ("Campaign against
Cancer and Heart Disease") was conducted in Washington
County, Maryland to establish a cohort with associated
blood samples [30]. At baseline, participants signed a con-
sent form, completed a brief medical and exposure history
and a food frequency questionnaire, and donated a blood
sample. The blood sample was collected in heparinzed
tubes and centrifuged to obtain separation of the buffy
coat which was then aliquotted and stored at -70°C. DNA
was subsequently extracted from the buffy coat using
standard phenol extraction [31].
A total of 25,081 persons (10,456 men and 14,625
women), about 30 percent of the Washington County res-
idents, participated in the study. In addition to the infor-
mation collected from this cohort at baseline in 1989,
follow-up data were obtained from questionnaires
administered in 1996 and approximately every 2 years
thereafter. The Institutional Review Board at the Johns
Hopkins Bloomberg School of Public Health approved
this study.
BBD cohort
The BBD cohort is a sub-set of CLUE II. Details of the
selection of CLUE II participants included in the BBD
cohort are described elsewhere [32]. Briefly, women who
responded on the 1996 CLUE II follow-up questionnaire
that they had undergone a "breast biopsy or lumpectomy"
were considered for inclusion into the BBD cohort.
Women were included in the BBD cohort if either they
were found to have BBD on their first located pathology
report or a pathology report was not found but a breast
biopsy was reported prior to or in the absence of a subse-
quent breast cancer diagnosis. Women who were diag-
nosed with breast cancer at their first biopsy, as reportedBMC Cancer 2006, 6:173 http://www.biomedcentral.com/1471-2407/6/173
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by the participant or as determined using the pathology
report search, were excluded from this analysis. In total, of
the 1683 women who reported that they had a breast
biopsy, 1467 women (87.2%) met the criteria above and
were included in the BBD cohort. Among these 1467
women, pathology report data were collected for 362
(24.7%). Seventy percent of these pathology reports indi-
cated a diagnosis of non-proliferative BBD, 26% indicated
a diagnosis of proliferative disease without atypia, and 4%
reported a diagnosis of proliferative disease with atypia.
For this analysis, 17 of the 1467 women were excluded
because DNA could not be obtained from their stored
blood samples and polymorphisms could not be geno-
typed. Further, all non-Caucasians (n = 12) were excluded
from the analysis because previous studies have shown
that race is an important confounder or effect modifier in
investigations of polymorphisms and disease. These
exclusions accounted from less than 1% of the BBD
cohort. After applying these exclusions, the final analytic
cohort included 1438 Caucasian women who were suc-
cessfully genotyped for at least one of the genetic poly-
morphisms investigated in this study.
Outcome measurement
Incident cases of in situ or invasive breast cancer (Interna-
tional Classification of Diseases, Ninth Revision, code
233, 174) were identified through linkage of the cohort
participants with the Washington County Cancer Registry
and, since 1992, with the Maryland State Cancer Registry.
The Washington County Cancer Registry identifies cancer
cases from discharge records and pathology reports from
Washington County Hospital, which is the only hospital
in the county, and from death certificates. Since 1992, all
hospitals cancer diagnostic laboratories, and radiation
therapy centers in Maryland have been required to report
incident cancer cases to the Maryland Cancer Registry, and
currently, the Maryland Cancer Registry is certified as
being more than 95% complete by the North American
Association of Central Cancer Registries. While it is possi-
ble that cases of in situ or invasive breast cancer may have
been missed due to migration out of the state after 1996,
all women in the BBD cohort had at least 7 years of fol-
low-up data (1989 to 1996). Further, approximately 80%
of the BBD cohort responded to the 2000 follow-up ques-
tionnaire, indicating that the vast majority of the cohort
remained under active surveillance in 2000.
Active case surveillance for the BBD cohort ended on April
28, 2003. In total, among all of the women included in
the BBD cohort, 15 incident cases of in situ and 76 cases of
invasive breast cancer were identified after the diagnosis
of BBD.
Genotyping
Single nucleotide polymorphisms (SNPs) analyzed in the
present study were selected as part of a larger study inves-
tigating the broad impact of genetic variation in candidate
genes and their interactions with environmental expo-
sures on cancer incidence and survival. For the larger
study, polymorphisms that were suggested to alter func-
tion, encoded for a nonsynonymous amino acid change,
or were located within the 5' or 3' untranslated region
(UTR) of the gene and thus could potentially alter mRNA
stability were chosen. Descriptions and dbSNP identifiers
of the polymorphisms selected are shown on Table 1.
Genotyping of the chosen SNPs in COMT, CYP1B1,
CYP1A1, ESR1 and ESR2 was conducted at Applied Bio-
systems (ABI) and Celera Laboratories. All polymor-
phisms were genotyped using TaqMan technology (ABI,
Foster City, CA, USA). The genotyping success rates of the
polymorphisms selected ranged from 91.8% to 97.6%,
with the exception of the CYP1B1 Arg48Gly polymor-
phism for which the genotyping success rate was 84.2%.
Table 1: Description of single nucleotide polymorphisms examined in the progression of BBD to breast cancer
Gene dbSNP rs # snp description Amino Acid Substitution
COMT 4680 Ex3-12G>A Val158Met
CYP1A1 1048943 Ex7+131A>G Ile462Val
CYP1B1 1800440 Ex3+315A>G Asn453Ser
CYP1B1 10012 Ex2+143C>G Arg48Gly
CYP1B1 1056836 Ex3+251G>C Val432Leu
ESR1 1801132 Ex4-122G>C Pro325Pro
ESR1 2077647 Ex1+392T>C Ser10Ser
ESR1 746432 Ex1-192G>C Ala87Ala
ESR1 2273206 IVS6+52G>T
ESR1 851982 -104062C>T
ESR1 2228480 Ex8+229G>A Thr594Thr
ESR2 4986938 38 bp 3' of STP C>T
ESR2 928554 5659 bp 3' of STP G>A
ESR2 none 5696 bp 3' of STP A>G
ESR2 8018687 5772 bp 3' of STP A>GBMC Cancer 2006, 6:173 http://www.biomedcentral.com/1471-2407/6/173
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The 84.2% genotyping success rate for CYP1B1 Arg48Gly
polymorphism was due to a problem with the laboratory
assay that was not resolved during the study period.
Statistical analysis
The outcome variable examined in these analyses was the
development of in situ or invasive breast cancer. Uncondi-
tional logistic regression was used to estimate age-
adjusted odds ratios (ORs) and 95% confidence intervals
(95% CIs) for the associations between the polymor-
phisms the development of breast cancer. Because previ-
ous studies indicate that the associations between several
of the analyzed polymorphisms and the development of
cancer may differ according to body mass index, smoking
status, and alcohol intake, we conducted exploratory anal-
yses to examine the associations between all of the poly-
morphisms and the development of breast cancer among
strata of these variables (BMI: <25 kg/m2,  ≥25 kg/m2;
smoking status: ever, never; alcohol intake: current, no
current use). Further, these analyses were conducted for
all participants and for pre- and post-menopausal partici-
pants separately. Because the number of events among the
pre-menopausal women was low (n = 24) and ORs for
some of the genotypes could not be calculated, only the
analyses for all participants and the post-menopausal sub-
group are reported. As an additional exploratory analysis,
logic regression [33] was employed using the software
package R 2.0.1 to examine whether any interactions
between the genotypes existed.
To address the issue of multiple testing in this study, p-val-
ues for the associations between single nucleotide poly-
morphisms and breast cancer risk were adjusted for the
false discovery rate using the method proposed by Ben-
jamini and Hochberg [34] in the software package R 2.0.1.
Unless otherwise specified, analyses were performed
using SAS Version 8.2 (Cary, NC). A p-value of less than
0.05 was considered to be statistically significant.
Results
Characteristics of the analytic cohort are reported in Table
2. The mean age of the participants was 53.5 years (stand-
ard deviation 12.1), and the majority of the women had
at least a high school degree (82.2%). Approximately 88%
of the women had been pregnant at least once in their life-
time, 16.2% were current smokers, and 28.8% were cur-
rent drinkers. Among the 1438 women in this sample, 91
(6.3%) developed invasive or in situ breast cancer after an
initial breast biopsy for BBD.
All of the polymorphisms examined were in Hardy-Wein-
berg equilibrium among women not developing breast
cancer, with the exception of the CYP1B1 Ile462Val poly-
morphism (p-value = 0.02). Although statistically signifi-
cant, the observed genotype counts for the CYP1B1
Ile462Val polymorphism were similar to the expected gen-
otype counts under Hardy-Weinberg equilibrium
(observed/expected: AA-1233/1229.5; AG-80/86.9; GG-
5/1.5). All ESR2 polymorphisms were in strong linkage
disequilibrium (D' > 90). Among the ESR1  polymor-
phisms, the Ser10Ser and Ala87Ala polymorphisms were
strongly linked (D' > 90).
The associations between polymorphisms in the estrogen
metabolizing enzymes and the risk of developing invasive
breast cancer among women with BBD are shown in Table
3. Among all participants and post-menopausal partici-
pants only, carriers of at least one CYP1B1 453Ser allele
had a borderline statistically significant increase in the
risk of developing breast cancer compared to women car-
rying the referent Asn/Asn genotype (all participants: OR
1.48, 95% CI 0.95, 2.32; post-menopausal participants:
OR 1.61; 95% CI 0.94, 2.74). The other polymorphisms
in the estrogen metabolizing enzymes were not associated
with breast cancer risk among women with BBD in this
study. Results were not substantially altered by BMI, alco-
hol intake or smoking status (results not shown). No sig-
nificant interactions between the genotypes were
observed. To note, after adjustment for multiple testing,
none of the associations between polymorphisms in the
estrogen metabolizing enzymes and the risk of developing
invasive breast cancer were statistically significant.
The associations between polymorphisms in ESR1  and
ESR2 and the risk of developing invasive breast cancer
among women with BBD are shown in Tables 4 and 5. A
marginally significant decrease in the risk of developing
breast cancer was observed among carriers of the ESR1 –
104062T allele compared to carriers of the referent geno-
type (all participants: OR 0.70, 95% CI 0.45, 1.09).
Among all participants, the ESR2 *5772G allele was asso-
ciated with a statistically significant decrease in the risk of
breast cancer among women with BBD (OR 0.38; 95% CI
0.15, 0.96). A marginally significant increase in the risk of
developing cancer was observed among women carrying
at least one ESR2 *38A allele compared to the women
homozygous for the GG genotype (all participants: OR
1.40; 95% CI 0.88, 2.25). OR estimates of the ESR2
*5772G and the ESR2 *38A polymorphisms were attenu-
ated after adjustment for the presence of the other poly-
morphism (ESR2 *5772G OR 0.42; 95% CI 0.17, 1.05;
ESR2 *38 OR 1.27; 95% CI 0.78, 2.04). Other ESR1 and
ESR2 polymorphisms examined were not associated with
breast cancer risk among women with BBD. Results did
not differ substantially by BMI, alcohol intake or smoking
status (results not shown). No significant interactions
between the ESR1 and ESR2  genotypes were observed.
After adjustment for multiple testing, the associationsBMC Cancer 2006, 6:173 http://www.biomedcentral.com/1471-2407/6/173
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Table 2: Characteristics of the study cohort (n = 1438)
Characteristic n %
Race
Caucasian 1438 100.0
Age, yearsa
<50 533 37.1
50 to 60 411 28.6
>60 494 34.3
Missing 0 0.0
Education, yearsa
less than a high school degree 259 18.0
high school degree 714 49.7
some college 463 32.2
Missing 2 0.1
Menopausal statusa
Pre-menopausal 377 26.2
Peri-menopausal 35 2.4
Post-menopausal 995 69.2
Missing 31 2.2
Family history of breast cancera
No 715 49.7
Yes 275 19.1
Missing 448 31.2
Ever been pregnant (%)b
No 176 12.2
Yes 1255 87.3
Missing 7 0.5
Age at first birth (years, %)b
Nulliparous 176 12.2
20 347 24.1
20 to 24 539 37.5
≥25 339 23.6
Missing 37 2.6
Age at menarche (years, %)b
<12 268 18.6
12 to 13 763 53.1
>13 386 26.8
Missing 21 1.5
Height, inchesa
<62 411 28.6
62–64 419 29.1
>64 608 42.3
Missing 0 0.0
Weight, poundsa
<130 354 24.6
130–<145 318 22.1
145–<165 377 26.2
≥165 387 26.9
Missing 2 0.1
BMI, kg/m2, a
<24.9 744 51.7
25.0 – 29.9 433 30.1
≥30 259 18.0
Missing 2 0.1
Smoking statusa
Never 839 58.3
Former 366 25.5
Current 232 16.1
Missing 1 0.1
Current alcohol drinkera
No 814 56.6BMC Cancer 2006, 6:173 http://www.biomedcentral.com/1471-2407/6/173
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between the ESR1 and ESR2 polymorphisms and breast
cancer described above were not statistically significant.
Discussion
In this population-based cohort of women with BBD,
there was evidence of an increased risk of breast cancer
among women who carried the CYP1B1 453Ser allele
compared to women who carried two copies of the
CYP1B1 453Asn allele. None of the previously published
studies on the CYP1B1 Asn453Ser polymorphism and
breast cancer conducted among average-risk women
reported an increase in risk of breast cancer associated
with this polymorphism [35-38], including a recent meta-
analysis that reported an OR of 0.91 (95% CI 0.79, 1.04)
associated with the heterozygous Asn/Ser genotype and an
OR of 0.85 (95% CI 0.54, 1.34) associated with the
homozygous Ser/Ser genotype [39]. However, functional-
ity studies demonstrate that the CYP1B1 polymorphic var-
iant is associated with both higher catalytic activity in
converting estrogen to 4-hydroxy estrogens and greater
levels of DNA damage [39-41]. This mechanism may be
more relevant for progression among the subgroup of
women with BBD who progress to breast cancer, thus it is
reasonable to examine this association among women
biopsy proven BBD.
A marginally significant positive association was observed
for the ESR2 *38G>A. This finding is not consistent with
results of published studies among either average-risk or
high-risk women. Maguire et al [26] reported no increase
in breast cancer risk associated with two copies of the var-
iant *38A allele among average-risk (OR 0.81; 95% CI
0.50, 1.31) or high risk (OR 1.00; 95% CI 0.58, 1.71). In
addition, Gold et al [16] observed that haplotypes con-
taining the common ESR2 *38G allele were associated
with an increased risk of breast cancer among Ashkenazi
Jews. These differences in findings may be due to the dif-
ferent populations under study; Maguire et al [26] exam-
ined ESR2 polymorphisms among patients in Sweden and
Gold et al (16) investigated ESR2  and breast cancer
among the Ashkenazi Jews. Neither investigated the asso-
ciation of ESR2  polymorphisms among women diag-
nosed with BBD.
In addition, results from this study suggest that women
with BBD who carry the ESR2 *5772A>G polymorphism
or the ESR1 – 104062C>T polymorphism are at decreased
risk of developing breast cancer. To our knowledge, nei-
ther of these genotypes has been examined in women
with BBD or among average risk women. The regions sur-
rounding each polymorphism are well conserved with lit-
tle recombination, therefore, it likely that, if the
associations are real, the observed associations are due to
linkage disequilibrium with another functional polymor-
phism in the region. No information on functionality is
know for either ESR2 *5772A>G or ESR1 – 104062C>T.
There was no evidence of an association between the
other polymorphisms examined in this study, including
those in COMT  and  CYP1A1, and breast cancer risk.
Although no published study has investigated the COMT
Val158Met and CYP1A1 Ile462Val polymorphisms in the
progression of BBD to invasive breast cancer, previous
studies of average-risk women have reported discrepant
results regarding the association between the COMT
Val158Met  and the CYP1A1 Ile462Val polymorphisms
and the risk of breast cancer [8,42]. Both polymorphisms
have been observed to be functional; the COMT 158Met
allele is associated with three- to four-fold decreased activ-
ity compared to the wildtype allele [43] and the CYP1A1
462Val  allele is consistent with higher enzyme activity
[44]. Therefore, an association between these polymor-
phisms and breast cancer is biologically plausible and
support the findings of studies that show an association
between the polymorphisms and breast cancer risk. It may
be, however, that both polymorphisms only modify the
association between endogenous estrogens and the risk of
breast cancer. Incorporating data on circulating estrogen
concentrations may clarify the importance of carrying a
specific genotype. Alternatively, it may also be that the
effect of any single polymorphisms on the risk of breast
cancer is small and that it is necessary to look at combina-
tions of variants in the hormone metabolism pathway.
While this study provides novel information regarding the
role of polymorphisms in estrogen metabolizing enzymes
and the estrogen receptor genes in the progression of BBD
to breast cancer, this study has several limitations inherent
to its design. As reported in a previously published inves-
tigation on this cohort of women [32], pathology reports
were not able to be obtained for all women who reported
that they had undergone a surgical biopsy. This was due
both to difficulties in obtaining permission for pathology
review for some participants as well as to an inability to
obtain records of biopsies done more than 15 to 20 years
ago. Since concordance of finding a pathology report and
report of biopsy among women granting permission for
pathology review who reported that they had undergone
Yes 413 28.7
Missing 211 14.7
a data from 1989 questionnaire
b data from 1996 questionnaire
Table 2: Characteristics of the study cohort (n = 1438) (Continued)BMC Cancer 2006, 6:173 http://www.biomedcentral.com/1471-2407/6/173
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a biopsy after 1980 was high (92.5%), all women who
reported a breast biopsy were included in the analyses.
However, this may have led to the inclusion of a small
number of women without BBD. Further, because data on
the type of BBD were not collected for all participants, the
analyses conducted in this study were not stratified by
type of BBD, and, therefore, the ORs reported may under-
estimate (or overestimate) the true associations among
women with certain types of BBD.
Table 3: Associations between estrogen metabolizing polymorphisms and breast cancer risk in the BBD cohort
Cancer No Cancer
dbSNP rs# (n = 91) (n = 1347) All Participants Post-
menopausal 
Only
n % n % Age- Adjusted 
OR (95% CI)
Age- Adjusted 
OR (95% CI)
COMT 
Val158Met
4680
GG 16 17.6 272 20.2 1.00 1.00
GA 41 45.1 608 45.1 1.15 (0.63, 2.08) 0.89 (0.45, 1.77)
AA 24 26.4 371 27.5 1.10 (0.57, 2.11) 0.90 (0.43, 1.90)
GA/AA 65 71.4 979 72.7 1.13 (0.64, 1.98) 0.89 (0.47, 1.70)
Missing 10 11.0 96 7.1
CYP1A1 
Ile462Val
1048943
AA 78 85.7 1233 91.5 1.00 1.00
AG 7 7.7 80 5.9 1.38 (0.62, 3.10) 1.30 (0.45, 3.74)
GG 1 1.1 5 0.4 3.33 (0.38, 
28.99)
8.33 (0.74, 
93.62)
p-for-trend 0.20 0.20
AG/GG 8 8.8 85 6.3 1.49 (0.70, 3.19) 1.56 (0.60, 4.08)
Missing 5 5.5 29 2.2
CYP1B1 
Asn453Ser
1800440
AA 51 56.0 866 64.3 1.00 1.00
AG 31 34.1 358 26.6 1.45 (0.91, 2.31) 1.51 (0.87, 2.65)
GG 4 4.4 37 2.7 1.77 (0.61, 5.16) 2.44 (0.81, 7.36)
p-for-trend 0.08 0.05
AG/GG 35 38.5 395 29.3 1.48 (0.95, 2.32) 1.61 (0.94, 2.74)
Missing 5 5.5 86 6.4
CYP1B1 
Arg48Gly
10012
CC 39 42.9 600 44.5 1.00 1.00
CG 33 36.3 460 34.1 1.10 (0.68, 1.78) 0.95 (0.53, 1.69)
GG 3 3.3 76 5.6 0.60 (0.18, 2.00) 0.25 (0.03, 1.88)
CG/GG 36 39.6 536 39.8 1.02 (0.65, 1.64) 0.84 (0.48, 1.50)
Missing 16 17.6 211 15.7
CYP1B1 
Val432Leu
1056836
CC 25 27.5 365 27.1 1.00 1.00
CG 39 42.9 653 48.5 0.88 (0.53, 1.48) 1.04 (0.56, 1.98)
GG 17 18.7 270 20.0 0.93 (0.49, 1.76) 0.93 (0.41, 2.09)
CG/GG 56 61.5 923 68.5 0.90 (0.55, 1.46) 1.01 (0.56, 1.85)
Missing 10 11.0 59 4.4BMC Cancer 2006, 6:173 http://www.biomedcentral.com/1471-2407/6/173
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Table 4: Associations between estrogen receptor-alpha (ESR1) polymorphisms and breast cancer risk in the BBD cohort
Cancer No Cancer
dbSNP rs# (n = 91) (n = 1347) All Participants Post-
menopausal 
Only
n % n % Age- Adjusted 
OR (95% CI)
Age-Adjusted 
OR (95% CI)
ESR1 Pro325Pro 1801132
CC 52 57.1 794 58.9 1.00 1.00
CG 31 34.1 440 32.7 1.07 (0.67, 1.69) 1.06 (0.61, 1.87)
GG 7 7.7 64 4.8 1.65 (0.72, 3.78) 2.03 (0.81, 5.10)
CG/GG 38 41.8 504 37.4 1.14 (0.74, 1.76) 1.19 (0.70, 2.01)
Missing 1 1.1 49 3.6
ESR1 Ser10Ser 2077647
TT 26 28.6 335 24.9 1.00 1.00
TC 36 39.6 642 47.7 0.71 (0.42, 1.20) 0.90 (0.46, 1.77)
CC 27 29.7 304 22.6 1.14 (0.65, 1.99) 1.88 (0.94, 3.75)
TC/CC 63 69.2 946 68.8 0.85 (0.53, 1.37) 1.21 (0.65, 2.24)
Missing 2 2.2 66 4.8
ESR1 Ala87Ala 746432
GG 67 73.6 1077 80.0 1.00 1.00
GC 15 16.5 181 13.4 1.32 (0.74, 2.36) 1.24 (0.61, 2.51)
CC 1 1.1 7 0.5 2.30 (0.28, 
18.95)
3.34 (0.38, 
29.18)
p-for-trend 0.3 0.3
GC/CC 16 17.6 188 14.0 1.36 (0.77, 2.39) 1.31 (0.66, 2.60)
Missing 8 8.8 82 6.1
ESR1 IVS6+52 2273206
GG 69 75.8 1060 78.7 1.00 1.00
GT 13 14.3 229 17.0 0.86 (0.48, 1.59) 0.71 (0.33, 1.53)
TT 3 3.3 10 0.7 4.79 (1.29, 
17.88)
5.31 (1.04, 
27.28)
GT/TT 16 17.6 239 17.7 1.02 (0.58, 1.79) 0.86 (0.43, 1.73)
Missing 6 6.6 48 3.6
ESR1 Thr594Thr 2228480
AA 2 2.2 41 3.0 1.00 1.00
AG 20 22.0 358 26.6 1.14 (0.26, 5.05) 0.88 (0.19, 4.04)
GG 58 63.7 841 62.4 1.42 (0.34, 6.01) 0.86 (0.20, 3.77)
AG/GG 78 85.7 1199 89.0 1.34 (0.32, 5.62) 0.87 (0.20, 3.75)
Missing 11 12.1 107 7.9
ESR1 – 
104062C>T
851982
CC 38 41.8 470 34.9 1.00 1.00
CT 33 36.3 612 45.4 0.65 (0.40, 1.05) 0.55 (0.30, 0.99)
TT 14 15.4 190 14.1 0.88 (0.47, 1.67) 0.89 (0.43, 1.85)
CT/TT 47 51.6 802 59.5 0.70 (0.45, 1.09) 0.63 (0.37, 1.08)
Missing 6 6.6 75 5.6BMC Cancer 2006, 6:173 http://www.biomedcentral.com/1471-2407/6/173
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In addition, though the base cohort is relatively large, the
number of cases of breast cancer occurring limited the
power of the study to make firm conclusions about the
relationships between polymorphisms in COMT,
CYP1B1, CYP1A1, ESR1 and ESR2 and the risk of breast
cancer in Caucasian women with BBD. We had limited
power to detect small associations and, therefore, were
also limited in our ability to correct for multiple testing.
As stated in the results section, the associations between
the polymorphisms and the risk of developing breast can-
cer were not statistically significant after correction for
multiple testing and this may have been due, in part, to
the small sample size. However, while we may be able to
rule out large changes in risk of clinical and public health
consequence associated with certain genotypes, we still
observed, with the small number of events, statistically
significant changes in the risk of breast cancer in this
cohort. Taken together with functional considerations of
these polymorphisms, it is important to follow-up on
these observations to determine if we can better under-
stand and perhaps intervene for those women with BBD
who are most at risk to progress to cancer.
Conclusion
The findings of this study indicate that specific polymor-
phisms in the CYP1B1, ESR1, and ESR2 genes may play a
role in progression of BBD to breast cancer among Cauca-
sian women. Although additional studies are needed to
Table 5: Associations between estrogen receptor-beta (ESR2) polymorphisms and breast cancer risk in the BBD cohort
Cancer No Cancer
(n = 91) (n = 1347) All Participants Post-
menopausal 
Only
dbSNP rs# n % n % Age- Adjusted 
OR (95% CI)
Age-Adjusted 
OR (95% CI)
ESR2 38 bp 3' of 
STP
4986938
GG 26 28.6 470 34.9 1.00 1.00
GA 43 47.3 612 45.4 1.27 (0.77, 2.10) 1.46 (0.80, 2.68)
AA 19 20.9 190 14.1 1.83 (0.99, 3.38) 1.71 (0.78, 3.76)
p-for-trend 0.06 0.1
GA/AA 62 68.1 802 59.5 1.40 (0.88, 2.25) 1.52 (0.85, 2.71)
Missing 3 3.3 75 5.6
ESR2 5659 bp 3' 
of STP
928554
GG 10 11.0 202 15.0 1.00 1.00
GA 44 48.4 632 46.9 1.41 (0.70, 2.86) 1.04 (0.48, 2.26)
AA 28 30.8 419 31.1 1.38 (0.66, 2.89) 0.88 (0.38, 2.05)
GA/AA 72 79.1 1051 78.0 1.40 (0.71, 2.76) 0.98 (0.47, 2.06)
Missing 9 9.9 94 7.0
ESR2 5696 bp 3' 
of STP
none
AA 75 82.4 1101 81.7 1.00 1.00
AG 12 13.2 180 13.4 0.96 (0.51, 1.81) 0.74 (0.33, 1.67)
GG 1 1.1 4 0.3 3.68 (0.41, 
33.37)
--
AG/GG 13 14.3 184 13.7 1.02 (0.56, 1.88) 0.73 (0.33, 1.64)
Missing 3 3.3 62 4.6
ESR2 5772 bp 3' 
of STP
8018687
AA 86 94.5 1133 84.1 1.00 1.00
AG 5 5.5 169 12.5 0.39 (0.16, 0.99) 0.62 (0.24, 1.59)
G G 00 . 050 . 4- - - -
AG/GG 5 5.5 174 12.9 0.38 (0.15, 0.96) 0.61 (0.24, 1.55)
Missing 0 0.0 40 3.0BMC Cancer 2006, 6:173 http://www.biomedcentral.com/1471-2407/6/173
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confirm or refute our findings, these results suggest that
genetic markers may aid in the identification of women
who are at risk for progression of BBD to cancer.
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